RBC Capital Maintains Outperform on CG Oncology, Raises Price Target to $79
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:CGON) with a Outperform and raises the price target from $73 to $79.
RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:CGON) with a Outperform and raises the price target from $73 to $79.